Cyclophosphamide and Febrile Neutropenia - Suspected Cause

Rx drug information, pharmaceutical research, clinical trials, news, and more

Drugs By Name

By Condition

By Category

Most Searched

Ratings/Reviews

Adverse Events

Actives

Rx Info

Summary Description and Clinical Pharmacology Indications and Dosage Warnings and Precautions Side Effects and Adverse Reactions Drug Interactions, Overdosage, Contraindications, Other Rx Info Active Ingredients Side Effect Reports

News & Research

Published Studies Curr't Clinical Trials

Index of reports > Cases with Febrile Neutropenia (521)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cyclophosphamide where reactions include febrile neutropenia. The selected reports were submitted to the FDA during the sample period of about a year.

Reports 1 - 30 of 521 Next >>

Possible Cyclophosphamide side effects in 65 year old female

Reported by a physician from Japan on 2012-08-24

Patient: 65 year old female, weighing 50.2 kg (110.6 pounds)

Reactions: Weight Decreased, Blood Bilirubin Increased, Cytomegalovirus Viraemia, Headache, Pyrexia, Interstitial Lung Disease, Oedema, Thrombocytopenia, Blood Sodium Decreased, Decreased Appetite, Vomiting, Stomatitis, Pneumonia, Alanine Aminotransferase Increased, Lymphopenia, Anaemia, Febrile Neutropenia, Rash, Blood Phosphorus Decreased, Blood Potassium Decreased, Diarrhoea, Alopecia, Aspartate Aminotransferase Increased, Neutropenia, Leukopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Adriamycin PFS
Dosage: 30 mg/m2 x 1/4 week
Start date: 2011-03-16

Adriamycin PFS
    Dosage: 40 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-09

Carboplatin
    Dosage: 250 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-24

Cyclophosphamide
    Dosage: 350 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-09

Etoposide
    Dosage: 100 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-24

Prednisolone
    Dosage: 40 mg/m2 x 1/4 week
    Administration route: Oral
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-09

Prednisolone
    Dosage: 1mg/kg x 1/2 week
    Start date: 2011-12-13
    End date: 2011-12-14

Prednisolone
    Dosage: 40 mg/m2 x 1/4 week
    Administration route: Oral
    Start date: 2011-03-16

Prednisolone
    Dosage: 2 mg/m2, 1x/day
    Administration route: Oral
    Start date: 2011-03-24

Ranimustine
    Dosage: 60 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-16

Vincristine Sulfate
    Dosage: 1 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-09

Vindesine Sulfate
    Dosage: 2.4 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-24

Other drugs received by patient: Mucosolvan; Lansoprazole; Sulfamethoxazole and Trimethoprim; Armodafinil; Zolpidem; Olopatadine HCL; Cefazolin Sodium; Ciprofloxacin HCL; Armodafinil; Zovirax; Magmitt; Alendronate Sodium

Possible Cyclophosphamide side effects in male

Reported by a physician from Germany on 2012-08-24

Patient: male

Reactions: Febrile Neutropenia, Skin Infection, Neutropenia, Pneumonitis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1500 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-02
    End date: 2012-04-17

Doxorubicin Hydrochloride
    Dosage: 100 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-02
    End date: 2012-04-17

Neulasta
    Dosage: 6 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-06
    End date: 2012-04-20

Prednisolone
    Dosage: 100 mg, unk
    Administration route: Oral
    Indication: B-Cell Lymphoma
    Start date: 2012-02-02
    End date: 2012-04-21

Rituximab
    Dosage: 750 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-01
    End date: 2012-04-16

Vincristine
    Dosage: 2 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-02
    End date: 2012-04-17

Other drugs received by patient: MST / 00036302 /; Novalgin / 00169801 /; Rulid; Pantoprazole; Paspertin / 00041902 /; Acyclovir; Electrolytes NOS W / Macrogol 3350; Dipyrone INJ; Metoclopramide; Acyclovir

Possible Cyclophosphamide side effects in female

Reported by a physician from United States on 2012-08-23

Patient: female

Reactions: Febrile Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-07-21

Cytarabine
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-07-17
    End date: 2012-07-20

Dasatinib
    Dosage: 40 milligram daily;
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-05-29

Mercaptopurine
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-07-13
    End date: 2012-07-21

Other drugs received by patient: Zofran; Miralax

Possible Cyclophosphamide side effects in

Reported by a physician from Japan on 2012-08-23

Patient:

Reactions: White Blood Cell Count Decreased, Stomatitis, Anaemia, Febrile Neutropenia, Constipation, Neutrophil Count Decreased

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 700 mg, qd
    Start date: 2010-10-26
    End date: 2010-10-26

Cyclophosphamide
    Dosage: 700 mg, qd
    Start date: 2010-12-07
    End date: 2010-12-07

Cyclophosphamide
    Dosage: 700 mg, qd
    Start date: 2010-11-16
    End date: 2010-11-16

Cyclophosphamide
    Dosage: 700 mg, once
    Indication: Breast Cancer
    Start date: 2010-09-29
    End date: 2010-10-29

Emend
    Dosage: 80 mg, qd
    Administration route: Oral
    Start date: 2010-10-27
    End date: 2010-10-28

Emend
    Dosage: 125 mg, qd
    Administration route: Oral
    Start date: 2010-12-07
    End date: 2010-12-07

Emend
    Dosage: 125 mg, once
    Administration route: Oral
    Indication: Prophylaxis of Nausea and Vomiting
    Start date: 2010-09-29
    End date: 2010-09-29

Emend
    Dosage: 125 mg, qd
    Administration route: Oral
    Start date: 2010-10-26
    End date: 2010-10-26

Emend
    Dosage: 80 mg, qd
    Administration route: Oral
    Start date: 2010-09-30
    End date: 2010-10-01

Emend
    Dosage: 80 mg, qd
    Administration route: Oral
    Start date: 2010-12-08
    End date: 2010-12-09

Emend
    Dosage: 80 mg, qd
    Administration route: Oral
    Start date: 2010-11-17
    End date: 2010-11-18

Emend
    Dosage: 125 mg, qd
    Administration route: Oral
    Start date: 2010-11-16
    End date: 2010-11-16

Epirubicin Hydrochloride
    Dosage: |100 mg, once
    Indication: Breast Cancer
    Start date: 2010-09-29
    End date: 2010-09-29

Epirubicin Hydrochloride
    Dosage: 100 mg, qd
    Start date: 2010-12-07
    End date: 2010-12-07

Epirubicin Hydrochloride
    Dosage: 100 mg, qd
    Start date: 2010-10-26
    End date: 2010-10-26

Epirubicin Hydrochloride
    Dosage: 100 mg, qd
    Start date: 2010-11-16
    End date: 2010-11-16

Other drugs received by patient: Granisetron Hydrochloride; Dexamethasone Sodium Phosphate; Mucosta; Decadron Phosphate; Dexamethasone Sodium Phosphate; Mucosta; Decadron Phosphate; Granisetron Hydrochloride; Mucosta; Mucosta; Granisetron Hydrochloride; Decadron Phosphate; Dexamethasone Sodium Phosphate; Granisetron Hydrochloride; Decadron Phosphate; Dexamethasone Sodium Phosphate

Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-08-23

Patient:

Reactions: Confusional State, White Blood Cell Count Decreased, Sepsis, Febrile Neutropenia, Encephalopathy, Platelet Count Decreased, Cystitis, Neutrophil Count Decreased

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Blinded Vorinostat
    Dosage: 400 mg, qd, on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-23
    End date: 2012-07-27

Cyclophosphamide
    Dosage: 750 mg/m2, once, on day 3
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-25

Doxorubicin Hydrochloride
    Dosage: 50 mg/m2, once, on day 3
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-25

Placebo
    Dosage: 400 mg, qd, on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-23
    End date: 2012-07-27

Prednisone TAB
    Dosage: 100 mg, qd, on days 3-7
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-25
    End date: 2012-07-29

Rituximab
    Dosage: 375 mg/m2, once, on day 3
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-25

Simvastatin
    Dosage: 400 mg, qd, on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-23
    End date: 2012-07-27

Vincristine Sulfate
    Dosage: 1.4 mg, once, on day 3
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-25